- Home
- NFJ vs COLL Comparison
NFJ vs COLL Comparison
Compare NFJ & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFJ
- COLL
- Stock Information
- Founded
- NFJ 2005
- COLL 2002
- Country
- NFJ United States
- COLL United States
- Employees
- NFJ N/A
- COLL N/A
- Industry
- NFJ Finance: Consumer Services
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- NFJ Finance
- COLL Health Care
- Exchange
- NFJ Nasdaq
- COLL Nasdaq
- Market Cap
- NFJ 1.1B
- COLL 947.6M
- IPO Year
- NFJ N/A
- COLL 2015
- Fundamental
- Price
- NFJ $12.03
- COLL $29.83
- Analyst Decision
- NFJ
- COLL Strong Buy
- Analyst Count
- NFJ 0
- COLL 4
- Target Price
- NFJ N/A
- COLL $43.75
- AVG Volume (30 Days)
- NFJ 223.5K
- COLL 269.0K
- Earning Date
- NFJ 01-01-0001
- COLL 08-07-2025
- Dividend Yield
- NFJ 9.01%
- COLL N/A
- EPS Growth
- NFJ N/A
- COLL N/A
- EPS
- NFJ N/A
- COLL 1.25
- Revenue
- NFJ N/A
- COLL $664,283,000.00
- Revenue This Year
- NFJ N/A
- COLL $20.04
- Revenue Next Year
- NFJ N/A
- COLL $3.98
- P/E Ratio
- NFJ N/A
- COLL $23.39
- Revenue Growth
- NFJ N/A
- COLL 17.17
- 52 Week Low
- NFJ $10.45
- COLL $23.23
- 52 Week High
- NFJ $12.86
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- NFJ 49.21
- COLL 55.48
- Support Level
- NFJ $12.00
- COLL $29.11
- Resistance Level
- NFJ $12.19
- COLL $30.22
- Average True Range (ATR)
- NFJ 0.13
- COLL 0.70
- MACD
- NFJ -0.04
- COLL -0.06
- Stochastic Oscillator
- NFJ 11.76
- COLL 49.89
About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.